Bill Gates and rich allies help fund an alt-biotech startup path for the gene expression experts at Exicure
Exicure CEO David Giljohann has been busy.
In the past couple of months, he’s rounded up two tranches of cash totaling $31.5 million from a growing band of backers, with Bill Gates coming back to join new, wealthy investor Fred Knoll in a syndicate that has strayed far off the typical startup funding path in biotech.
But that’s not his only divergence from the standard course. He’s executed a “clean” reverse merger with a completely empty shell to go out onto the OTC market — not Nasdaq. And, back in the norm, he’s followed up on his first round of Phase I data with plans to line up a series of Phase II studies to put his platform tech to a crucial test.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
